A late-stage Chinese biotech in one of the hottest areas of drug development has corralled 500 million Chinese yuan (about $72 million) in a Series C from OrbiMed, Qiming Venture Partners and other investors, according ...
China obesity biotech QL Biopharm gets $72M, including support from OrbiMed
